Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 9:14:1119837.
doi: 10.3389/fphar.2023.1119837. eCollection 2023.

Association of variations in the CAT and prognosis in lung cancer patients with platinum-based chemotherapy

Jia-Si Liu  1   2   3 , Jun-Yan Liu  4 , Qi Xiao  1   2   3 , Xiang-Ping Li  5 , Juan Chen  2   3   5 , Zhao-Qian Liu  1   2   3
Affiliations

Association of variations in the CAT and prognosis in lung cancer patients with platinum-based chemotherapy

Jia-Si Liu et al. Front Pharmacol. .

Abstract

PURPOSE: To explore the relationship between ATM, ATR and CAT polymorphisms and prognosis of lung cancer patients received platinum-based chemotherapy. METHODS: 404 patients with lung cancer who received platinum-chemotherapy were enrolled and DNA typing was performed. Cox regression analysis and stratification analyses was performed to assess relationships between OS and PFS with SNPs genotypes. The prognosis of lung adenocarcinomaand squamous cell carcinomapatients was analyzed with The Cancer Genome Atlas (TCGA) database according to the grouping of CAT expression. RESULTS: CAT rs769217 was significantly related to PFS of patients with lung cancer who received platinum-chemotherapy. In the Additive model, rs769217 was associated with PFS (HR = 0.747, 95% CI = 0.581-0.960, p = 0.023). In the Dominant model, CT and TT genotypes led to lung cancer progression 0.738 times more than CC genotype. In stratification analyses of association between CAT rs769217 polymorphisms and PFS, the HR of patients at stage IV in additive model was 0.73, and HR was 0.745 (p = 0.034) in dominant model. For OS analyses, HR was 0.672 in the older lung cancer patients (>55 years old) in additive model. Meanwhile, in the Dominant model, it was found that the older patients with CT and TT genotypes had better prognosis, and the risk of death after receiving platinum-based chemotherapy was 0.692 times that of patients with CC genotype (p = 0.037). TCGA data shows that LUAD patients with high CAT expression have longer OS (p = 0.020). CONCLUSION: CAT rs769217 is significantly related to PSF of platinum-based chemotherapy in lung cancer patients and may be a biomarker for predicting the prognosis of lung cancer patients with platinum-based chemotherapy.

Keywords: ATM; ATR; cat; lung cancer; platinum-based chemotherapy; precious medicine; snps.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
The Kaplan-Meier plot of COX proportional hazards regression analysis, (A) Additive model, (B) Dominant model, (C) Recessive model.
FIGURE 2
FIGURE 2
Association of CAT rs769217 and PFS in Stratification analyses, (A) additive model, (B) Dominant model, (C) Recessive model. p* <0.05, p**< 0.01.
FIGURE 3
FIGURE 3
Association of CAT rs769217 and OS in Stratification analyses, (A) additive model, (B) Dominant model, (C) Recessive model. p* <0.05, p**< 0.01.
FIGURE 4
FIGURE 4
Association of the expression of CAT with lung cancer OS (A) and PFS (B) in TCGA LUAD and LUSC patients.
See this image and copyright information in PMC

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71, 209–49. 10.3322/caac.21660 - DOI - PubMed
    1. Pagani M, Bavbek S, Alvarez-Cuesta E, Berna Dursun A, Bonadonna P, Castells M, et al. (2022). Hypersensitivity reactions to chemotherapy: an EAACI Position Paper. Allergy 77, 388–403. 10.1111/all.15113 - DOI - PubMed
    1. Reck M, Remon J, Hellmann MD. (2022). First-Line Immunotherapy for Non-Small-Cell Lung Cancer. official journal of the American Society of Clinical Oncology 40, 586–97. 10.1200/JCO.21.01497 - DOI - PubMed
    1. Yu C, Wang Z, Sun Z, Zhang L, Zhang W, Xu Y, et al. (2020). Platinum-Based Combination Therapy: Molecular Rationale, Current Clinical Uses, and Future Perspectives. Journal of medicinal chemistry 63, 13397–412. 10.1021/acs.jmedchem.0c00950 - DOI - PubMed
    1. Ahmad S. (2010). Platinum-DNA interactions and subsequent cellular processes controlling sensitivity to anticancer platinum complexes. CHEMISTRY & BIODIVERSITY 7, 543–66. 10.1002/cbdv.200800340 - DOI - PubMed